S&P 500   3,321.75 (+0.03%)
DOW   29,186.27 (-0.03%)
QQQ   223.87 (+0.26%)
AAPL   317.70 (+0.36%)
FB   221.32 (-0.05%)
MSFT   165.70 (-0.48%)
GOOGL   1,484.17 (+0.13%)
AMZN   1,887.46 (-0.24%)
CGC   24.12 (-0.12%)
NVDA   250.05 (+0.85%)
BABA   222.37 (+0.05%)
MU   59.17 (+0.34%)
GE   11.37 (-2.49%)
TSLA   569.56 (+4.09%)
AMD   51.43 (+0.74%)
T   39.04 (+1.35%)
ACB   2.04 (+1.49%)
F   9.16 (-0.54%)
PRI   126.65 (+0.19%)
BAC   34.36 (+0.29%)
DIS   144.01 (+0.31%)
GILD   63.43 (+1.28%)
S&P 500   3,321.75 (+0.03%)
DOW   29,186.27 (-0.03%)
QQQ   223.87 (+0.26%)
AAPL   317.70 (+0.36%)
FB   221.32 (-0.05%)
MSFT   165.70 (-0.48%)
GOOGL   1,484.17 (+0.13%)
AMZN   1,887.46 (-0.24%)
CGC   24.12 (-0.12%)
NVDA   250.05 (+0.85%)
BABA   222.37 (+0.05%)
MU   59.17 (+0.34%)
GE   11.37 (-2.49%)
TSLA   569.56 (+4.09%)
AMD   51.43 (+0.74%)
T   39.04 (+1.35%)
ACB   2.04 (+1.49%)
F   9.16 (-0.54%)
PRI   126.65 (+0.19%)
BAC   34.36 (+0.29%)
DIS   144.01 (+0.31%)
GILD   63.43 (+1.28%)
S&P 500   3,321.75 (+0.03%)
DOW   29,186.27 (-0.03%)
QQQ   223.87 (+0.26%)
AAPL   317.70 (+0.36%)
FB   221.32 (-0.05%)
MSFT   165.70 (-0.48%)
GOOGL   1,484.17 (+0.13%)
AMZN   1,887.46 (-0.24%)
CGC   24.12 (-0.12%)
NVDA   250.05 (+0.85%)
BABA   222.37 (+0.05%)
MU   59.17 (+0.34%)
GE   11.37 (-2.49%)
TSLA   569.56 (+4.09%)
AMD   51.43 (+0.74%)
T   39.04 (+1.35%)
ACB   2.04 (+1.49%)
F   9.16 (-0.54%)
PRI   126.65 (+0.19%)
BAC   34.36 (+0.29%)
DIS   144.01 (+0.31%)
GILD   63.43 (+1.28%)
S&P 500   3,321.75 (+0.03%)
DOW   29,186.27 (-0.03%)
QQQ   223.87 (+0.26%)
AAPL   317.70 (+0.36%)
FB   221.32 (-0.05%)
MSFT   165.70 (-0.48%)
GOOGL   1,484.17 (+0.13%)
AMZN   1,887.46 (-0.24%)
CGC   24.12 (-0.12%)
NVDA   250.05 (+0.85%)
BABA   222.37 (+0.05%)
MU   59.17 (+0.34%)
GE   11.37 (-2.49%)
TSLA   569.56 (+4.09%)
AMD   51.43 (+0.74%)
T   39.04 (+1.35%)
ACB   2.04 (+1.49%)
F   9.16 (-0.54%)
PRI   126.65 (+0.19%)
BAC   34.36 (+0.29%)
DIS   144.01 (+0.31%)
GILD   63.43 (+1.28%)
Log in
(Ad)
A devastating technical glitch could crush the next generation of wireless technology before it even launches. With trillions of dollars and millions of jobs at stake, one company with the "5G fix" could put as much as $234,770 in your pocket this year. But Wall Street vultures are circling... you'll need to move quickly or risk missing this $5 bargain.

NASDAQ:ONCE - Spark Therapeutics Stock Price, Forecast & News

$113.57
0.00 (0.00 %)
(As of 01/22/2020 04:00 PM ET)
Add
Compare
Today's Range
$113.57
Now: $113.57▼
$113.57
50-Day Range
$109.79
MA: $112.85▼
$114.48
52-Week Range
$34.53
Now: $113.57▼
$114.20
VolumeN/A
Average Volume419,933 shs
Market Capitalization$4.37 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.05
Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. The company's gene therapy product candidates comprise SPK-8011 and SPK-8016 for hemophilia; SPK-7001 for choroideremia; and SPK-9001 for hemophilia B. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ONCE
Previous Symbol
CUSIPN/A
CIK1609351
Webhttp://www.sparktx.com/
Phone888-772-7560

Debt

Debt-to-Equity Ratio0.35
Current Ratio4.67
Quick Ratio4.35

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$64.72 million
Price / Sales67.59
Cash FlowN/A
Price / Cash FlowN/A
Book Value$13.15 per share
Price / Book8.64

Profitability

EPS (Most Recent Fiscal Year)($2.11)
Net Income$-78,820,000.00
Net Margins-358.41%
Return on Equity-59.10%
Return on Assets-33.13%

Miscellaneous

Employees368
Outstanding Shares38,520,000
Market Cap$4.37 billion
Next Earnings Date2/18/2020 (Estimated)
OptionableOptionable

Receive ONCE News and Ratings via Email

Sign-up to receive the latest news and ratings for ONCE and its competitors with MarketBeat's FREE daily newsletter.

NASDAQ:ONCE Rates by TradingView

(Ad)

Join a small community of investors looking for the next big winner. Every Sunday reveals 3 compelling stocks that should be on your radar for the week ahead. Sign up here to see what stocks have made it to our watchlist this week.

Spark Therapeutics (NASDAQ:ONCE) Frequently Asked Questions

What is Spark Therapeutics' stock symbol?

Spark Therapeutics trades on the NASDAQ under the ticker symbol "ONCE."

How were Spark Therapeutics' earnings last quarter?

Spark Therapeutics Inc (NASDAQ:ONCE) announced its earnings results on Thursday, November, 7th. The biotechnology company reported ($1.72) EPS for the quarter, missing the consensus estimate of ($1.21) by $0.51. The biotechnology company earned $22.45 million during the quarter, compared to the consensus estimate of $25.39 million. Spark Therapeutics had a negative return on equity of 59.10% and a negative net margin of 358.41%. View Spark Therapeutics' Earnings History.

When is Spark Therapeutics' next earnings date?

Spark Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for Spark Therapeutics.

What price target have analysts set for ONCE?

11 analysts have issued 12-month price targets for Spark Therapeutics' shares. Their forecasts range from $47.00 to $115.00. On average, they expect Spark Therapeutics' stock price to reach $106.00 in the next twelve months. This suggests that the stock has a possible downside of 6.7%. View Analyst Price Targets for Spark Therapeutics.

What is the consensus analysts' recommendation for Spark Therapeutics?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spark Therapeutics in the last year. There are currently 11 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Spark Therapeutics.

What are Wall Street analysts saying about Spark Therapeutics stock?

Here are some recent quotes from research analysts about Spark Therapeutics stock:
  • 1. According to Zacks Investment Research, "Spark Therapeutics, Inc. offers gene therapy. The Company's product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in Philadelphia, Pennsylvania. " (12/3/2019)
  • 2. William Blair analysts commented, "We see a sound strategic fit with Roche given its recent investment in hemophilia with the launch of Hemlibra (SPK-8011 in hemophilia A, SPK-8016 in hemophilia A patients with inhibitors and royalties from the fidanacogene elaparvovec collaboration with Pfizer), ophthalmology (Luxturna in the United States and royalties from the Luxturna EU launch), and neuroscience (SPK-1001 for CLN2) franchises." (2/26/2019)

Has Spark Therapeutics been receiving favorable news coverage?

Headlines about ONCE stock have trended positive recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Spark Therapeutics earned a news sentiment score of 3.0 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Spark Therapeutics.

Who are some of Spark Therapeutics' key competitors?

What other stocks do shareholders of Spark Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spark Therapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Alibaba Group (BABA), NVIDIA (NVDA), Gilead Sciences (GILD), AbbVie (ABBV), Micron Technology (MU), Exelixis (EXEL), Celgene (CELG), Netflix (NFLX) and BioMarin Pharmaceutical (BMRN).

Who are Spark Therapeutics' key executives?

Spark Therapeutics' management team includes the folowing people:
  • Mr. Jeffrey D. Marrazzo, Co-Founder, CEO & Director (Age 40)
  • Dr. Katherine A. High, Co-Founder, Pres, Head of R&D and Director (Age 67)
  • Mr. Stephen W. Webster, Chief Financial Officer (Age 58)
  • Mr. Joseph W. La Barge Esq., J.D., Chief Legal Officer & Sec. (Age 48)
  • Mr. Daniel R. Faga, Chief Bus. Officer (Age 39)

When did Spark Therapeutics IPO?

(ONCE) raised $88 million in an IPO on Friday, January 30th 2015. The company issued 5,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Cowen and Company and Sanford C. Bernstein were co-managers.

How do I buy shares of Spark Therapeutics?

Shares of ONCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Spark Therapeutics' stock price today?

One share of ONCE stock can currently be purchased for approximately $113.57.

How big of a company is Spark Therapeutics?

Spark Therapeutics has a market capitalization of $4.37 billion and generates $64.72 million in revenue each year. The biotechnology company earns $-78,820,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Spark Therapeutics employs 368 workers across the globe.View Additional Information About Spark Therapeutics.

What is Spark Therapeutics' official website?

The official website for Spark Therapeutics is http://www.sparktx.com/.

How can I contact Spark Therapeutics?

Spark Therapeutics' mailing address is 3737 MARKET STREET SUITE 1300, PHILADELPHIA PA, 19104. The biotechnology company can be reached via phone at 888-772-7560 or via email at [email protected]


MarketBeat Community Rating for Spark Therapeutics (NASDAQ ONCE)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  502 (Vote Outperform)
Underperform Votes:  424 (Vote Underperform)
Total Votes:  926
MarketBeat's community ratings are surveys of what our community members think about Spark Therapeutics and other stocks. Vote "Outperform" if you believe ONCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONCE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/22/2020 by MarketBeat.com Staff

Featured Article: What is a Call Option?
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel